CoagulationDisorders near Bronx, NY

Biography: Benjamin Samstein, MD is Chief of Liver Transplantation and Hepatobiliary Surgery in the Department of Surgery at NewYork-Presbyterian/Weill Cornell Medicine and Associate Professor of Surgery at Weill Cornell Medical College, Cornell University. Dr. Samstein is the Surgical Director of the Living Donor Liver Transplant Program at NYP. Dr. Samstein is a renowned pioneer in minimally invasive liver surgery and state-of-the-art laparoscopic techniques for liver cancer. Dr. Samstein is a Castle Connolly Top Doctor. Dr. Samstein heads up the multidisciplinary liver transplantation and hepatobiliary surgery team at NYP/Weill Cornell. His specialties include the most advanced laparoscopic procedures for liver cancer, benign liver tumors and hepatobiliary pancreatic disease. He has been invited to talk about minimally invasive liver surgery throughout the world. He is a member of many surgical societies including a founding member of the International Laparoscopic Liver Society (ILLS), American Society of Transplant Surgery, American Hepato-Pancreato-Biliary Association (AHPBA). He is the Chair of the Medical Advisory Board of LiveOnNY and served as the Regional representation to the Liver and Intestine Committee of UNOS from 2014 to 2016. Dr. Samstein is well-published in the field, authoring more than 40 peer-reviewed articles in prestigious medical and surgical journals, books and book chapters. Other areas of clinical expertise include hepatic adenoma, hepatic hemangioma, cholangiocarcinoma, colorectal metastasis, live donor nephrectomy, laparoscopic living donor nephrectomy, and pediatric liver and organ transplant. Dr. Samstein received his undergraduate degree from Cornell University in 1992 and earned his MD at the State University of New York at Stonybrook in 1997. He did his internship and residency in general surgery at NYP/Columbia, and completed a research fellowship at the Mayo Clinic in 2001. He completed a fellowship in ASTS Multi-organ transplant at NYP/Columbia in 2006. He was Assistant Professor of Surgery at Columbia University Medical Center from 2006 to 2015. He served as Program Director of the transplant surgery fellowship at Columbia University from 2007 to 2015. He is a reviewer for American Journal of Transplantation, Transplantation, Liver Transplantation, Pediatric Transplantation, Clinical Transplantation among other journals. List of Publications by Dr. Samstein PubMed

Biography: Dr. Amengual is the Herbert Irving Associate Professor of Medicine in the Division of Hematology and Oncology, Center for Lymphoid Malignancies, and Hebert Irving Comprehensive Cancer Center here at Columbia University Irving Medical Center. Dr. Amengual obtained a degree in Nutritional Sciences at Cornell University where she graduated with honors. She attained her Medical Doctorate from New York Medical College, followed by a residency in Internal Medicine at Montefiore Medical Center/Albert Einstein College of Medicine. Dr. Amengual then went on to complete her fellowship in Hematology and Oncology at the NYU Langone Medical Center, where she participated in the Physician-Scientist Training Program and graduated as a Dean's Scholar. She is the recipient of several awards and scholarships for her research, including the Irving Scholarship, the Gabrielle's Angel Foundation for Cancer Research and as a Scholar of the Amos Medical Faculty Development Award Robert Wood Johnson Foundation and the American Society of Hematology. She was also selected to participate in the prestigious American Association for Cancer Research (AACR)/American Society of Clinical Oncology (ASCO) Vail Workshop Methods in Clinical Cancer Research, the European Hematology Association/American Society of Hematology Translational Research Training Program and the South West Oncology Group (SWOG) Leadership Academy. These competitive programs select the most promising faculty for enriched development and have laid the foundation for her research. She has now served on the faculty or review committee of several of these programs. As an R01-funded physician-scientist, Dr. Amengual is focused on translating the latest scientific discoveries regarding cancer cell behavior into novel treatment platforms. She aims to translate observations and concepts developed in the laboratory directly into patient care. Specifically, she is focused on combination epigenetic targeting for both B-cell and T-cell lymphomas. She continues to develop new pharmacologic strategies directed at altering these diseases at their genetic roots, now collaborating with investigators from backgrounds of diverse scientific expertise. Dr. Amengual has been studying the effects HDAC inhibitors in combination with EZH2 inhibitors to capitalize on two common mutations driving growth of diffuse large B-cell lymphoma cells. In addition, she has studied targeting the BCL6:p53 pathway in order to shift the balance of oncogene and tumor suppressor function using novel therapeutic approaches. For T-cell lymphoma Dr. Amengual has led a clinical trial combining HDAC inhibitors with the novel antifolate drug, pralatrexate. The pralatrexate plus romidepsin combination has led to dramatic responses in patients with relapsed T-cell lymphoma and will serve as the basis of more trials to come aimed at improving outcomes with patients with these diseases. Building on these discoveries, Dr. Amengual is now evaluating the interplay of epigenetics with immune surveillance and endogenous retroviral expression in the setting of lymphoma. Dr. Amengual has lectured at academic institutions and conferences around the world, and at forums such as the Lymphoma Research Foundation and the American Hematology Society's Highlights of ASH. She has published numerous chapters and peer reviewed articles on the biology and treatment of lymphoma, and serves as a Scientific Reviewer for a number of journals in the field, including Journal of Clinical Oncology and as an Editorial Board Member of Clinical Cancer Research. She has sat on grant review and abstract review committees for meetings such as the American Society of Hematology where she has also chaired sessions, American Society of Clinical Oncology and the Doris Duke Charitable Foundation. She is actively involved in the NCI's National Clinical Trial Network, SWOG, as a Lymphoma Working Group Committee Member. Dr. Amengual is involved in numerous clinical trials for lymphoma, enabling our patients to access the best opportunities for the treatment of their disease. Dr. Amengual has clinical expertise in lymphoma, HIV- and EBV-related hematologic illnesses.

Biography: Dr. Amy Tiersten, MD is a Hematology Specialist who practices in New York, NY. She is 61 years old and has been practicing for 35 years. Dr. Amy Tiersten, MD is affiliated with Mount Sinai Hospital.

Biography: Dr. Ingham is Assistant Professor of Medicine in the Division of Hematology and Oncology at New York Presbyterian Hospital/Columbia University Medical Center. He received his medical degree from the University of Massachusetts Medical School and completed internship and residency training in Internal Medicine at New York University Medical Center, where he served as Chief Resident. He then completed fellowship training in Hematology and Medical Oncology at New York Presbyterian Hospital/Columbia University Medical Center where he served as Chief Fellow. Dr. Ingham specializes in the care of patients with sarcoma and gastrointestinal cancers and is also an active member of the experimental therapeutics unit. His research focuses on the development and clinical evaluation of new treatments for patients with sarcoma. He leads a National Cancer Institute (NCI) sponsored clinical trial evaluating a new treatment approach for uterine leiomyosarcoma based on research conducted at Columbia University. He also leads several other investigator-initiated clinical trials evaluating new targeted and immunotherapy based treatment approaches for leiomyosarcoma, liposarcoma and other types of sarcoma. He is the author of two recent authoritative reviews on the treatment of sarcoma published in the Journal of Clinical Oncology. He is the recipient of the 2019 Conquer Cancer Foundation of ASCO Career Development Award from the Sarcoma Foundation of America in recognition of his research and was also named a 2019 NextGen Innovator by HemOnc Today, among other awards and honors. His overall goal is to provide patients with compassionate oncologic care and access to the most promising treatment approaches.

Care Philosophy: We are committed to delivering the best care and an exceptional patient experience We are devoted to providing services that are patient centered and compassionate and care for you as a person nbsp;

Biography: Dr. Julie Fasano, MD is a Hematology Specialist who practices in New York, NY. She is 52 years old and has been practicing for 23 years. Dr. Julie Fasano, MD is affiliated with Mount Sinai Hospital.

Biography: Juliet Barker, MBBS (Hons), FRACP, is an Australian trained hematologist. Having been an Attending Member and Physician at Memorial Sloan Kettering Cancer Center (MSKCC) and the Director of the MSKCC Cord Blood (CB) Transplantation Program, Dr. Barker has been recruited to Weill Cornell Medicine and NewYork-Presbyterian Hospital as the Director of the Bone Marrow Transplant and Cellular Therapy Program.Over the last 25 years, Dr. Barker has worked to expand transplant access to minority patients with hematologic malignancies and has demonstrated the ability of cord blood transplantation to provide curative therapy for such populations without suitable adult donors. Dr. Barker's work in this area has been internationally recognized and she has published extensively concerning novel strategies to optimize access to donor transplants and cord blood transplant outcomes. Additionally, she has a special focus on optimizing complex health care delivery such as hematopoietic stem cell transplantation in under-served populations. Dr. Barker has advised the National Marrow Donor Program (NMDP) and is a member of the Advisory Council on Blood Stem Cell Transplantation to the Health Resources and Services Administration of the U.S. government. She has served on the American Society for Transplantation and Cellular Therapy (ASTCT) Board and led the national ASTCT Cord Blood Special Interest Group. Having previously served as Associate Vice Chair, Faculty Development, in the Department of Medicine at MSKCC, Dr. Barkeralso has a keen interest in academic mentorship.

Biography: Dr. Emond is the Vice Chairman of Surgery at Columbia University. He has over 30 years of experience performing liver transplantation and complex liver and biliary surgery in children and adults, including the first living donor liver transplantation (LDLT) in the United States. Dr. Emond has published extensively in this field and was the co-chair of the NIH A2ALL program for 13 years. In collaboration with the department of Medicine at Columbia, Dr. Emond recruited the leadership of the Columbia Center for Translational immunology that created the foundation for translational and clinical research in transplantation tolerance. This will lead the way to inducing transplant tolerance in liver patients with the mixed chimerism strategy. As Director of Transplantation at the Columbia University Medical Center Dr. Emond's activities foster clinical excellence and research across all 11 of the solid organ transplant programs at the Medical Center. In recognition of his national and international leadership in transplantation, Dr. Emond is the past president of the American Society of Transplant Surgeons, the pre-eminent association of a transplant surgery. Contribution to Science Living donor liver transplantation Dr. Emond has spent a substantial portion of his career developing living donor liver transplantation and studying the safety of the procedure in both the donor and recipient. He participated in the first living donor liver transplant in the United States and focused on refining the techniques of performing living donor liver transplants and split liver transplants. He was the national co-chair of the NIH-sponsored Adult-to-Adult Living Donor Liver Transplantation (A2ALL) consortium from 2002 to 2015 to study the safety and outcomes of living donor liver transplants. Hepatic resection/ischemia Dr. Emond developed techniques for surgical resection of liver tumors and studied the effect of ischemia during resection on postoperative liver function. These studies include the outcomes of the extent of hepatectomy, the biochemical response to major hepatectomy and ischemia-reperfusion injury of the liver in rodent models. He has studied the clinical safety of inducing total vascular exclusion to provide a bloodless field during the liver transection. This has applications in both liver cancer and living donor hepatectomies. Hepatocellular carcinoma treatment Dr. Emond has studied many aspects of managing patients with hepatocellular carcinoma. These studies have included characterizing the risk factors for recurrence of disease following transplantation due to comorbidities and tumor characteristics. The research team has also studied the optimal method of preventing tumor growth in patients with HCC on the liver transplant wait list in addition to optimal strategies of liver allocation to optimize outcomes following liver transplantation. These studies have contributed to proposed changes in UNOS exception point allocation for liver transplant candidates with HCC. Pediatric liver transplantation Dr. Emond helped develop the field of pediatric liver transplantation. Contributions to this field include: the use of living donors for pediatric patients; use of auxiliary liver transplants for metabolic diseases; use of partial liver grafts for pediatric patients; and technical modifications that improved outcomes for this patient population. Visit The Center for Liver Disease and Transplantation at columbiasurgery.org/liver